CD8A and neoplasm: In this scenario, BRAF mutant CRCs (BRAF-CRCs) represent a heterogeneous tumor entity with a high frequency of MSI and/or CD8+ tumors [16,17] that urgently deserve to be investigated to predict both tumor antigenicity and the level of tumor inflammation for potential eligibility for immunotherapy treatments.